Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12542386 | 1.00 | CCR2 (0.47) | CCR2JAK2TYK2JAK3CACNA1B | |
| SCHEMBL12542382 | 1.00 | CCR2 (0.47) | CCR2JAK2TYK2JAK3CACNA1B | |
| SCHEMBL12543356 | 0.87 | CCR2 (0.47) | CCR2JAK2TYK2JAK3CACNA1B | |
| SCHEMBL12543355 | 0.87 | CCR2 (0.47) | CCR2JAK2TYK2JAK3CACNA1B | |
| SCHEMBL12688736 | 0.87 | KDM4E (0.37) | CCR2 | |
| SCHEMBL12688542 | 0.86 | CCR2 (0.43) | CCR2CACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12542081 | 0.86 | CCR2 (0.43) | CCR2CACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12542083 | 0.86 | CCR2 (0.43) | CCR2CACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12541766 | 0.84 | CCR2 (0.49) | CCR2CACNA1BCYP3A4CYP2C19 | |
| SCHEMBL12541768 | 0.84 | CCR2 (0.49) | CCR2CACNA1BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | CCR2 2244/4885JAK2 2406/4885TYK2 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.